Today, DISPENDIX, a BICO company, announced that the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022.

Driven by several years of growth of the I.DOT non-contact Dispenser, DISPENDIX has invested in strategic R&D and industry partnerships to deliver two disruptive platforms that will come together to provide scientists with more holistic workflow solutions for genomics and drug discovery research.

The I.DOT HT builds on the core technology of the I.DOT, expanding the source well layout to a 384 format to support the management of compound libraries at large pharmaceutical and smaller biotechnology companies. The I.DOT HT provides the same degree of precision and process safety that users have come to expect from the DISPENDIX family of products, while expanding the applicability of the I.DOT; now users can seal and store source plates that contain compound libraries for assay development, optimization, and screening.

DISPENDIX has also announced the introduction of the L.DROP Liquid Handler with the goal of commoditizing laboratory automation. “We have brought in experts from outside the life-science industry to deliver a delightfully architected web-based liquid handler”, says Petros Apostolopoulos, CEO of DISPENDIX. “We can’t wait to show customers that automated liquid handling doesn’t have to be a challenge to implement and how to use it in a reliable and efficient way.”

The L.DROP couples sensor technology and a web-based architecture to provide a more dynamic instrument that is capable of scaling protocols across instruments and even laboratories without tedious optimization.  Features like automated deck calibration, web-based protocol fitting, and closed-loop pipetting promise to revolutionize the way that researchers and automation engineers leverage liquid handling technologies.

“As disruptive innovators in the liquid handling space, we are pleased to launch novel solutions for the scientific community on our journey to create the future of health,” says Petros Apostolopoulos, CEO of DISPENDIX. “With the I.DOT HT and the L.DROP we are excited to introduce two groundbreaking instruments. Both can be fully integrated into the ‘lab of the future’ that is data-driven and optimizes researchers time spent on scientific discovery.”

This launch is the latest in DISPENDIX’s mission to deliver simple and elegant solutions for the liquid handling industry. These products will be on display and demoed at the upcoming SLAS (Society for Laboratory Automation and Screening) in Boston from February 7-9, 2022 at booth 2727.

More information about the products can be found at Dispendix.com.

For more information:

BICO Press office Sweden  
Hedda Söderström, Communications Manager: +46 73509 2261 
E-mail: press@bico.com 

This information was submitted for publication, through the agency of the contact persons set out above, on February 2, 2022, at 15:00 (CET).

About DISPENDIX

DISPENDIX GmbH, the premier provider of noncontact liquid handling solutions in the nano to microliter range, started out in 2016 as a spin-off from the Fraunhofer Institute for Manufacturing Engineering and Automation (IPA) in Stuttgart, Germany. In 2018, DISPENDIX joined the world’s leading bio convergence company BICO, which now encompasses 1,200+ colleagues and 14 companies, offering a portfolio of technologies, products and services to create the future of health. Part of that portfolio is DISPENDIX’s patented and widely recognized technology, the I.DOT (Immediate Drop-on-demand Technology), which brings intuitive automation, precision and speed to every lab, allowing scientists to optimize liquid handling workflows and accelerate their research in a range of applications. DISPENDIX’S Liquid handling technology enables new discoveries in areas such as drug development, diagnostics and synthetic biology. We believe that technological advances and science are made for each other. Good technology simplifies science. www.dispendix.com

About BICO

Founded in 2016, BICO
(formerly CELLINK)is the leading bio convergence company in the world.By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.

The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.

The Groups instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO.www.bico.com   

Contact us!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.